REN Therapeutics is an innovative biotech company that develops oral microbiome therapies to treat chronic kidney disease. The company is a spin-out of BEO Therapeutics that develops microbiome treatments counteract diseases caused by modern lifestyle.
In EU, US and Japan more 9 mio patients develop chronic kidney disease (CDK) as a consequence of elevated uremic toxins. CDK causes a decline in kidney function that may ultimately result in the need for dialysis and kidney transplant.
REN Therapeutics first product is a drug that will prevent the progression of CDK without the contraindications of current treatments.